Chinese english Germany Japanese Korea

Cyclobutanecarboxylic acid, 1-(3-methyl-5-isoxazolyl)-

Cyclobutanecarboxylic acid, 1-(3-methyl-5-isoxazolyl)- Struktur
1535427-10-1
CAS-Nr.
1535427-10-1
Englisch Name:
Cyclobutanecarboxylic acid, 1-(3-methyl-5-isoxazolyl)-
Synonyma:
1-(3-Methylisoxazol-5-yl)cyclobutanecarboxylic acid;Cyclobutanecarboxylic acid, 1-(3-methyl-5-isoxazolyl)-;1-(3-Methyl-1,2-oxazol-5-yl)cyclobutane-1-carboxylic acid
CBNumber:
CB78310706
Summenformel:
C9H11NO3
Molgewicht:
181.19
MOL-Datei:
1535427-10-1.mol
Request For Quotation

Cyclobutanecarboxylic acid, 1-(3-methyl-5-isoxazolyl)- Eigenschaften

Siedepunkt:
358.2±30.0 °C(Predicted)
Dichte
1.311±0.06 g/cm3(Predicted)
pka
3.80±0.20(Predicted)

Sicherheit

Cyclobutanecarboxylic acid, 1-(3-methyl-5-isoxazolyl)- Chemische Eigenschaften,Einsatz,Produktion Methoden

Cyclobutanecarboxylic acid, 1-(3-methyl-5-isoxazolyl)- Upstream-Materialien And Downstream Produkte

Upstream-Materialien

Downstream Produkte

Cyclobutanecarboxylic acid, 1-(3-methyl-5-isoxazolyl)- Anbieter Lieferant Produzent Hersteller Vertrieb Händler.

Global( 7)Lieferanten
Firmenname Telefon E-Mail Land Produktkatalog Edge Rate
Nantong HI-FUTURE Biology Co., Ltd. 		+undefined18051384581
 sales@chemhifuture.com China 3136 58
Guangzhou Isun Pharmaceutical Co., Ltd 020-39119399 18927568969
 isunpharm@qq.com China 4428 55
Nantong Hi-Future Biotechnology Co., Ltd 18051384581
 sales@chemhifuture.com China 3058 58
Bide Pharmatech Ltd. 400-1647117 15221909166
 product02@bidepharm.com China 63720 58
Bide Pharmatech Ltd. 400-6005915
sales@picasso-e.com China 39668 58
Beijing Solarbio Science & Tecnology Co., Ltd. 010-50973130 17801761073
 Gsiyu@solarbio.com China 50751 58
Shanghai Jieshikai Biotechnology Co. , Ltd. 021-57520305 15026420323
 sunchao@jskchem.com China 49242 58
  • Cyclobutanecarboxylic acid, 1-(3-methyl-5-isoxazolyl)-
  • 1-(3-Methyl-1,2-oxazol-5-yl)cyclobutane-1-carboxylic acid
  • 1-(3-Methylisoxazol-5-yl)cyclobutanecarboxylic acid
  • 1535427-10-1
Copyright 2019 © ChemicalBook. All rights reserved